CSL AAQS 2024
CSL AAQS
9
Ticker
CSL.AX
ISIN
AU000000CSL8
WKN
890952
CSL ima trenutni AAQS od 9. Visoki AAQS može se smatrati pozitivnim pokazateljem da se poduzeće uspješno razvija. Investitori mogu očekivati da je poduzeće na dobrom putu da ostvaruje dobit. S druge strane, važno je usporediti AAQS dionice CSL s ostvarenim dobitima i drugim poduzećima iste industrije. Visoki AAQS nije apsolutna garancija za pozitivnu budućnost. Samo tako možemo dobiti potpunu sliku o performansi poduzeća. Da bi bolje procijenili razvoj poduzeća, važno je usporediti AAQS s drugim poduzećima iste industrije. Generalno, investitori bi uvijek trebali razmatrati AAQS poduzeća u kontekstu s drugim financijskim pokazateljima poput dobiti, EBIT-a, Cash Flow-a i drugih kako bi donijeli obrazloženu investicijsku odluku.
CSL Aktienanalyse
Što radi CSL?
CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL ist eines der beliebtesten Unternehmen auf Eulerpool.com.Česta pitanja o CSL dionici
Aktiensparpläne nude atraktivnu mogućnost za investitore za dugoročno stvaranje imovine. Jedna od glavnih prednosti je tzv. efekt prosječenja troškova: investirajući redovito fiksni iznos u dionice ili dioničke fondove, automatski se kupuje više udjela kada su cijene niske, a manje kada su visoke. To može dovesti do povoljnijeg prosječnog cijene po udjelu tijekom vremena. Osim toga, Aktiensparpläne omogućavaju i malim investitorima pristup skupim dionicama, jer mogu sudjelovati već s malim iznosima. Redovita investicija također promiče discipliniranu strategiju ulaganja i pomaže izbjeći emocionalne odluke, poput impulzivne kupnje ili prodaje. Pored toga, investitori profitiraju od potencijalnog povećanja vrijednosti dionica kao i od isplata dividendi koje mogu biti reinvestirane, što pojačava učinak kamatnog kamata i time rast uloženog kapitala.
Dionica CSL je dostupna za štedne planove kod sljedećih pružatelja usluga: Consorsbank
Andere Kennzahlen von CSL
Naša analiza dionica CSL Prihod uključuje važne financijske pokazatelje kao što su prihod, dobit, P/E omjer, P/S omjer, EBIT, kao i informacije o dividendi. Također, razmatramo aspekte poput dionica, tržišne kapitalizacije, dugova, vlastitog kapitala i obveza CSL Prihod. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama nudimo opsežne analize: